Management of endometrial cancer in Asia: consensus statement from the Asian Oncology Summit 2009

The Lancet Oncology

Volumn 10, Issue 11, 2009, Pages 1119-1127

  Tangjitgamol, Siriwan ^a   Anderson, Benjamin O ^b   See, Hui Ti ^c   Lertbutsayanukul, Chawalit ^d   Sirisabya, Nakarin ^d   Manchana, Tarinee ^d   Ilancheran, Arunachalam ^e   Lee, Khai Mun ^e   Lim, Siew Eng ^e   Chia, Yin Nin ^f   Domingo, Efren ^g   Kim, Young Tak ^h   Lai, Chyong Huey ⁱ   Dali, Ahmad Zailani Hatta Mohd ^j   Supakapongkul, Wisit ^k   Wilailak, Sarikapan ^l   Tay, Eng Hseon ^m   Kavanagh, John ^d  

^a NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c GLENEAGLES HOSPITAL   (Singapore)

^d CHULALONGKORN UNIVERSITY   (Thailand)

^e NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^f KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^g UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^h University of Ulsan   (South Korea)

ⁱ CHANG GUNG UNIVERSITY   (Taiwan)

^j UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^k NATIONAL CANCER INSTITUTE   (Thailand)

^l MAHIDOL UNIVERSITY   (Thailand)

^m Thomson Medical Centre   (Singapore)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ASIA; BONE MARROW SUPPRESSION; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SCREENING; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; EXTERNAL BEAM RADIOTHERAPY; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; LYMPH NODE DISSECTION; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESOURCE ALLOCATION; REVIEW; SOCIOECONOMICS; TRANSVAGINAL ECHOGRAPHY;

ASIA; CHEMOTHERAPY, ADJUVANT; CONGRESSES AS TOPIC; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DRUG COSTS; EARLY DIAGNOSIS; ENDOMETRIAL NEOPLASMS; EVIDENCE-BASED MEDICINE; FEMALE; GUIDELINE ADHERENCE; GYNECOLOGIC SURGICAL PROCEDURES; HEALTH CARE COSTS; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HORMONE REPLACEMENT THERAPY; HUMANS; LYMPH NODE EXCISION; MASS SCREENING; MEDICAL ONCOLOGY; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 71249155601     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70290-6     Document Type: Review

References (71)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Sherman M.E. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 13 (2000) 295-308
3. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105 (2009) 103-104
4. ASTEC study group, Kitchener H., Swart A.M., Qian Q., Amos C., and Parmar M.K. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373 (2009) 125-136
5. Panici P.B., Basile S., Maneschi F., et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100 (2008) 1707-1716
6. ASTEC/EN.5 Study Group, Blake P., Swart A.M., et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 373 (2009) 137-146
7. Anderson B.O., Yip C.H., Smith R.A., et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer 113 (2008) 2221-2243
8. Smith R.A., Cokkinides V., and Brawley O.W. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 59 (2009) 27-41
9. Brown G.J., St John D.J., Macrae F.A., and Aittomäki K. Cancer risk in young women at risk of hereditary nonpolyposis colorectal cancer: implications for gynecologic surveillance. Gynecol Oncol 80 (2001) 346-349
10. Consensus Statement. Recommendations for follow-up care of individuals with an inherited predisposition to cancer: I hereditary nonpolyposis colon cancer. JAMA 277 (1997) 915-919
11. Dijkhuizen F.P., Mol B.W., Brolmann H.A., and Heintz A.P. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 89 (2000) 1765-1772
12. Goldstein S. The role of transvaginal ultrasound or endometrial biopsy in the evaluation of the menopausal endometrium. Am J Obstet Gynecol 201 (2009) 5-11
13. Miller D.S., and King L.P. Gynecologic oncology group trials in uterine corpus malignancies: recent progress. J Gynecol Oncol 19 (2008) 218-222
14. Malur S., Possover M., Michels W., and Schneider A. Laparoscopic-assisted vaginal versus abdominal surgery in patients with endometrial cancer-a prospective randomized trial. Gynecol Oncol 80 (2001) 239-244
15. Ramondetta L., Burke T., Broaddus R., and Jhingran A. Treatment of endometrial cancer. In: Eifel P.J., Gershenson D.M., Kavanagh J.J., and Silva E.G. (Eds). The MD Anderson Cancer Care Series: Gynecologic Cancer (2006), Springer-Verlag, New York 152-153
16. Ayhan A., Taskiran C., Celik C., and Yuce K. The long-term survival of women with surgical stage II endometrioid type endometrial cancer. Gynecol Oncol 93 (2004) 9-13
17. Creasman W.T., Morrow C.P., Bundy B.N., Homesley H.D., Graham J.E., and Heller P.B. Surgical pathologic spread patterns of endometrial cancer (a Gynecologic Oncology Group Study). Cancer 60 (1987) 2035-2041
18. Larson D.M., Johnson K.K., Broste S.K., Krawisz B.R., and Kresl J.J. Comparison of D&C and office endometrial biopsy in predicting final histopathologic grade in endometrial cancer. Obstet Gynecol 86 (1995) 38-42
19. Goff B.A., and Rice L.W. Assessment of depth of myometrial invasion in endometrial adenocarcinoma. Gynecol Oncol 38 (1990) 46-48
20. Noumoff J., Menzin A., Mikuta J.J., Lusk E.J., Morgan M., and LiVolsi V.A. The ability to evaluate prognostic variables on frozen section in hysterectomies performed for endometrial carcinoma. Gynecol Oncol 42 (1991) 202-208
21. Fishman D.A., Roberts K.B., Chambers J.T., Kohorn E.I., Schwartz P.E., and Chambers S.K. Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium. Gynecol Oncol 61 (1996) 189-196
22. Grigsby P.W., Kuske R.R., Perez C.A., et al. Medically inoperable stage I adenocarcinoma of the endometrium treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 13 (1987) 483-488
23. Rouanet P., Dubois J.B., Gely S., and Pourquier H. Exclusive radiation therapy in endometrial carcinoma. Int J Radiat Oncol Biol Phys 26 (1993) 223-228
24. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 106 (2005) 413-425
25. Havrilesky L.J., Cragun J.M., Calingaert B., et al. Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecol Oncol 99 (2005) 689-695
26. Cragun J.M., Havrilesky L.J., Calingaert B., et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 23 (2005) 3668-3675
27. Lutman C.V., Havrilesky L.J., Cragun J.M., et al. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol 102 (2006) 92-97
28. Shuster L.T., Rhodes D.J., Gostout B.S., Grossardt B.R., and Rocca W.A. Premature menopause or early menopause: long-term health consequences. Maturitas (2009) 10.1016/j.maturitas.2009.08.003 published online Aug 3.
29. Wright J.D., Buck A.M., Shah M., Burke W.M., Schiff P.B., and Herzog T.J. Safety of ovarian preservation in premenopausal women with endometrial cancer. J Clin Oncol 27 (2009) 1214-1219 10;
30. Richter C.E., Qian B., Martel M., et al. Ovarian preservation and staging in reproductive-age endometrial cancer patients. Gynecol Oncol 114 (2009) 99-104
31. Morrow C.P., Bundy B.N., Kurman R.J., et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 40 (1991) 55-65
32. Mariani A., Webb J.M., Keeney L.G., Aletti G., and Podratz C.K. Assessment of prognostic factors in stage IIIA endometrial cancer. Gynecol Oncol 86 (2002) 38-44
33. Alektiar K.M. When and how should adjuvant radiation be used in early endometrial cancer?. Semin Radiat Oncol 16 (2006) 158-163
34. Aalders J., Abeler V., Kolstad P., and Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma. Obstet Gynecol 56 (1980) 419-427
35. Creutzberg C.L., van Putten W.L., Koper P.C., et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355 (2000) 1404-1411
36. Scholten A.N., van Putten W.L., Beerman H., et al. Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 63 (2005) 834-838
37. Keys H.M., Roberts J.A., Brunetto V.L., et al. A phase 3 trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92 (2004) 744-751
38. Creutzberg C.L., van Putten W.L., Koper P.C., et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol 89 (2003) 201-209
39. Johnson N., and Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. BJOG 114 (2007) 1313-1320
40. Nout R.A., Putter H., Jürgenliemk-Schulz I.M., et al. Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: results of the randomized PORTEC-2 trial. J Clin Oncol 26 suppl (2008) abstr LBA5503.
41. Beriwal S., Jain S.K., Heron D.E., et al. Clinical outcome with adjuvant treatment of endometrial carcinoma using intensity-modulated radiation therapy. Gynecol Oncol 102 (2006) 195-199
42. Mundt A.J., Roeske J.C., Lujan A.E., et al. Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. Gynecol Oncol 82 (2001) 456-463
43. Mundt A.J., Mell L.K., and Roeske J.C. Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int J Radiat Oncol Biol Phys 56 (2003) 1354-1360
44. Bouchard M., Nadeau S., Gingras L., et al. Clinical outcome of adjuvant treatment of endometrial cancer using aperture-based intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 71 (2008) 1343-1350
45. Lewis G.C., Slack N.H., Mortel R., and Bross I. Adjuvant progestagen therapy in the definitive treatment of endometrial cancer. Gynecol Oncol 2 (1974) 368-376
46. MacDonald R.R., Thorogood J., and Mason M.K. A randomised trial of progestagens in the primary treatment of endometrial carcinoma. Br J Obstet Gynaecol 95 (1988) 166-174
47. Vergote I., Kjorstad K., Abeler V., and Kolstad P. A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer 64 (1989) 1011-1016
48. COSA-NZ-UK Endometrial Cancer Study Group. Adjuvant medroxyprogesterone acetate in high-risk endometrial cancer. Int J Gynecol Cancer 8 (1998) 387-391
49. Martin-Hirsch P.L., Jarvis G., Kitchener H., and Lilford R. Progestagens for endometrial cancer. Cochrane Database System Rev 4 (1999) CD001040.
50. Magrath I. Chemotherapy in developing countries-is less better?. Eur J Cancer 39 (2003) 1497-1550
51. Humber C.E., Tierney J.F., Symonds R.P., et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol 18 (2007) 409-420
52. Morrow C.P., Bundy B.N., Homesley H.D., et al. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study. Gynecol Oncol 36 (1990) 166-171
53. Randall E.M., Filiaci L.V., Muss H., et al. Randomized phase 3 trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 24 (2006) 36-44
54. Maggi R., Lissoni A., Spina F., et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 95 (2006) 266-271
55. Susumu N., Sagae S., Udagawa Y., et al., Japanese Gynecologic Oncology Group. Randomized phase 3 trial of pelvis radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate and high risk endometrial cancer. A Japanese Gynecologic Oncology Group Study. Gynecol Oncol 108 (2008) 226-233
56. Homesley H.D., Filiaci V., Gibbons S.K., et al. Randomized phase 3 trial in advanced endometrial carcinoma of surgery and volume-directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol 108 (2008) 2
57. Homesley H.D. Present status and future direction of clinical trials in advanced endometrial carcinoma. J Gynecol Oncol 19 (2008) 157-161
58. Huh W.K., Powell M., Leath III C.A., et al. Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol 91 (2003) 470-475
59. Vandenput I., Van Calster B., Capoen A., et al. Br J Cancer 101 (2009) 244-249
60. Barakat R.R., Goldman N.A., Patel D.A., Venkatraman E.S., and Curtin J.P. Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol 75 (1999) 99-102
61. Campagnutta E., Giorda G., De Piero G., et al. Surgical treatment of recurrent endometrial carcinoma. Cancer 100 (2004) 89-96
62. Barlin J.N., Ueda S.M., and Bristow R.E. Cytoreductive surgery for advanced and recurrent endometrial cancer: a review of the literature. Womens Health (Lond Engl) 5 (2009) 403-411
63. Thigpen J.T., Blessing J.A., DiSaia P.J., Yordan E., Carson L.F., and Evers C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 12 (1994) 1408-1414
64. Fleming G.F., Brunetto V.L., Cella D., et al. Phase 3 Trial of Doxorubicin and cisplatin with or without paclitaxel plus filgrastim in advanced endometrial cancer. J Clin Oncol 22 (2004) 2159-2166
65. Thigpen J.T., Brady M.F., Alvarez R.D., et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose response study by the Gynecologic Oncology Group. J Clin Oncol 17 (1999) 1736-1744
66. Tangjitgamol S., Manusirivithaya S., Hanprasertpong J., and Kavanagh J.J. Hormone replacement therapy after treatment of endometrial cancer. Gynecol Obstet Invest 65 (2008) 35-38
67. Barakat R.R., Bundy B.N., Spirtos N.M., Bell J., and Mannel R.S. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol 24 (2006) 587-592
68. Rossouw J.E., Anderson G.L., Prentice R.L., et al., Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
69. Committee on Gynecologic Practice. ACOG committee opinion. Hormone replacement therapy in women treated for endometrial cancer. Number 234, May 2000 (replaces number 126, August 1993). Int J Gynaecol Obstet 73 (2001) 283-284
70. Fung-Kee-Fung M., Dodge J., Elit L., Lukka H., Chambers A., and Oliver T. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol 101 (2006) 520-529
71. Tjalma W.A., van Dam P.A., Makar A.P., and Cruickshank D.J. The clinical value and the cost-effectiveness of follow-up in endometrial cancer patients. Int J Gynecol Cancer 14 (2004) 931-937